scholarly journals Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial

2020 ◽  
Vol 72 (3) ◽  
pp. 334-342 ◽  
Author(s):  
Anita Patel ◽  
Margaret Heslin ◽  
David L. Scott ◽  
Dominic Stringer ◽  
Fraser Birrell ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Tumor Necrosis ◽  
Active Rheumatoid Arthritis ◽  
Multicenter Trial ◽  
Tumor Necrosis Factor Inhibitors ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying ◽  
Necrosis Factor

scholarly journals Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

2021 ◽  
pp. jrheum.210984
Author(s):  
Paul Studenic ◽  
Helga Radner
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Synthetic Dmards ◽  
Disease Modifying ◽  
Necrosis Factor

Patients with rheumatoid arthritis (RA) have come to experience a tremendous increase in therapeutic options with disease-modifying antirheumatic drugs (DMARDs).1 After decades of dissatisfying drug therapy results with conventional synthetic DMARDs (csDMARDs) only, the introduction of the first tumor necrosis factor inhibitors in the late 1990s has revolutionized RA treatment.2

scholarly journals MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

2018 ◽  
Vol 11 (11) ◽  
pp. 47 ◽  
Author(s):  
Salmi Abdul Razak ◽  
Mohd Makmor-bakry ◽  
Adyani Md Redzuan
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Special Consideration ◽  
Biologic Therapies ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Factor Inhibitor ◽  
Disease Modifying ◽  
Necrosis Factor

Rheumatoid arthritis (RA) is a progressive chronic inflammatory disease affecting 0.5–1.0% of the adult population worldwide. Due to the damages caused by this autoimmune disease, new biologic therapies, particularly the biologic disease-modifying antirheumatic drugs (bDMARDs), are now being the treatment of choice in the management of RA. However, special precaution and prescreening before the usage of bDMARDs are needed to ensure better clinical response and avoiding risk of adverse event during treatment with the selected bDMARDs. In this review paper, we will provide overview on the incidence and pathogenesis of the disease, available pharmacological treatment and emphasizing special consideration in need on initiation of bDMARDs among RA patients. A literature review was performed by searching for relevant articles in Medline database through PubMed using medical subject headings terms and keywords: RA, bDMARDs, special consideration, tumor necrosis factor inhibitor, and non-tumor necrosis factor inhibitor. All papers reviewed were from 1999 to 2017 and were written in English. In this article, use of conventional synthetic DMARDs (csDMARDs), bDMARDs and special consideration to be taken upon initiation of biologic therapies in RA will be reviewed.

scholarly journals Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Delphine Dénarié ◽  
Mélanie Rinaudo-Gaujous ◽  
Thierry Thomas ◽  
Stéphane Paul ◽  
Hubert Marotte
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis ◽  
Large Range ◽  
Methotrexate Therapy ◽  
Tnf Alpha ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Blood Samples ◽  
Disease Modifying ◽  
Necrosis Factor

Objectives. To evaluate methotrexate effect on tumor necrosis factor (TNF) alpha bioactivity during infliximab (IFX) therapy in rheumatoid arthritis (RA) patients and to correlate TNF bioactivity with antibody towards IFX (ATI) development and RA clinical response. Materials and Methods. Thirty-nine active women RA patients despite conventional synthetic disease modifying antirheumatic drugs (csDMARDs) requiring IFX therapy were enrolled, and clinical data and blood samples were recorded at baseline (W0) and at 6 weeks (W6), W22, and W54 of IFX treatment. TNF bioactivity as well as IFX trough and ATI concentrations were assessed on blood samples. Results. TNF bioactivity decreased from W0 to W54 with a large range from W22 at the time of ATI detection. From W22, TNF bioactivity was lower in presence of methotrexate as csDMARD compared to other csDMARDs. IFX trough concentration increased from W0 to W54 with a large range from W22, similarly to TNF bioactivity. Methotrexate therapy prevented ATI presence at W22 and reduced TNF bioactivity compared to other csDMARDs (p=0.002). Conclusion. This suggests that methotrexate plays a key role in TNF bioactivity and against ATI development.

Sign in / Sign up

Export Citation Format

Share Document